Emerging evidence links cannabis use to increased risk of breast and testicular cancer in young Americans

Introduction: The aim of this study was to test the a priori hypothesis that the increasing incidence of testis and breast cancer in adolescent and young adult (AYA) Americans correlates with their increasing cannabis use. Methods: The overall study design involved comparing breast and testis cancer incidence trends in jurisdictions that had or had not legalized cannabis use. Cancer incidence was assessed for the U.S. using the U.S. Surveillance, Epidemiology, and End Results (SEER) data, and for Canada, using Institute for Health Metrics and Evaluation data. Results: In the U.S., both breast carcinoma in 20- to 34-year-old females and testis cancer in 15- to 39-year-old males had annual incidence rate increases that were highly correlated (Pearson’s r = 0.95) with the increase in the number of cannabis-legalizing jurisdictions during the period 2000–2019. Both were significantly greater during the period 2000–2019 in the SEER registries of cannabis-legalizing than non-legalizing states (Joinpoint-derived average annual percent change, AAPC1.3, p << 0.001 vs. 0.7, p << 0.001, respectively, for breast cancer, and AAPC1.2, p << 0.001 vs. no increase during the period 2000–2011 for testis cancer). During the period 2000–2019, registries in cannabis-legalizing versus non-legalizing states had a 26% versus 17% increase in breast carcinoma and 24% versus 14% increase in testis cancer. In the same age groups, Canada had a greater increase in both breast and testis cancer incidence than the U.S., and in both countries, breast and cancer trends were both correlated with the country’s cannabis use disorder prevalence by age. Conclusions: North America shows evidence that cannabis is a potential etiologic factor contributing to the rising incidence of breast carcinoma and testis cancer in young adults. Canada’s greater increases than in the U.S. are consistent with its earlier and broader cannabis legalization. Given the increasing use and potency of cannabis facilitated by jurisdiction legalization and expanded availability, cannabis’ potential as a cause of breast and testis cancer merits national consideration.

Authors

Institutions

Publication Details

Journal
Academia oncology.
Published
2025-06-06
DOI
https://doi.org/10.20935/acadonco7758
Citations
1
Primary Topic
Cannabis and Cannabinoid Research
Type
article
Field-Weighted Citation Impact
1.39
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Emerging evidence links cannabis use to increased risk of breast and testicular cancer in young Americans

Rebecca H. Johnson, Franklin Chien, Archie Bleyer, Ashley Speckhart
1 citations
Academia oncology.
Cannabis and Cannabinoid Research
1.39
article

Emerging evidence links cannabis use to increased risk of breast and testicular cancer in young Americans

Rebecca H. Johnson, Franklin Chien, Archie Bleyer, Ashley Speckhart
article en
1 citations

Abstract

Introduction: The aim of this study was to test the a priori hypothesis that the increasing incidence of testis and breast cancer in adolescent and young adult (AYA) Americans correlates with their increasing cannabis use. Methods: The overall study design involved comparing breast and testis cancer incidence trends in jurisdictions that had or had not legalized cannabis use. Cancer incidence was assessed for the U.S. using the U.S. Surveillance, Epidemiology, and End Results (SEER) data, and for Canada, using Institute for Health Metrics and Evaluation data. Results: In the U.S., both breast carcinoma in 20- to 34-year-old females and testis cancer in 15- to 39-year-old males had annual incidence rate increases that were highly correlated (Pearson’s r = 0.95) with the increase in the number of cannabis-legalizing jurisdictions during the period 2000–2019. Both were significantly greater during the period 2000–2019 in the SEER registries of cannabis-legalizing than non-legalizing states (Joinpoint-derived average annual percent change, AAPC1.3, p << 0.001 vs. 0.7, p << 0.001, respectively, for breast cancer, and AAPC1.2, p << 0.001 vs. no increase during the period 2000–2011 for testis cancer). During the period 2000–2019, registries in cannabis-legalizing versus non-legalizing states had a 26% versus 17% increase in breast carcinoma and 24% versus 14% increase in testis cancer. In the same age groups, Canada had a greater increase in both breast and testis cancer incidence than the U.S., and in both countries, breast and cancer trends were both correlated with the country’s cannabis use disorder prevalence by age. Conclusions: North America shows evidence that cannabis is a potential etiologic factor contributing to the rising incidence of breast carcinoma and testis cancer in young adults. Canada’s greater increases than in the U.S. are consistent with its earlier and broader cannabis legalization. Given the increasing use and potency of cannabis facilitated by jurisdiction legalization and expanded availability, cannabis’ potential as a cause of breast and testis cancer merits national consideration.

Academia oncology.Vol. 2(2)
MultiCare Health System (US), Emory University (US), Oregon Health & Science University (US), MaineHealth (US), Center for Cancer and Blood Disorders (US), Children's Healthcare of Atlanta (US)
Openalex Percentile: Top 20%
Cannabis and Cannabinoid Research
1.39
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.